ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Channel Therapeutics Corporation (CHRO) stock surged +7.14%, trading at $1.35 on AMEX, up from the previous close of $1.26. The stock opened at $1.25, fluctuating between $1.23 and $1.48 in the recent session.
Channel Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
Employees | 4 |
Beta | 3.29 |
Sales or Revenue | N/A |
5Y Sales Change% | -1% |
Fiscal Year Ends | N/A |
Sector | Healthcare |
Industry | Biotechnology |
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep